Old HIV drugs get a second look in Long-Term study
NCT ID NCT01125228
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 5 times
Summary
This study compares three treatments for early HIV infection: zidovudine (AZT) alone, alpha-interferon alone, or both together. It aims to see which best lowers viral load, protects the immune system, and delays the first serious infection. About 180 adults with early HIV and healthy immune systems are taking part, with long-term follow-up to track outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zidovudine (AZT) and alpha-interferon
- What this could lead to
- If successful, this could show which early HIV treatment better controls the virus and delays opportunistic infections.
- What could go wrong
- This is an older study from before modern HIV treatments (HAART), so results may not apply to current care. Side effects from both drugs can be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer support may lift the cloud of loneliness for older gay men with HIV
- Can peer mentors help gay men with HIV stay in care?
- HIV and hidden health risks: a major study probes the link
- Faith-Based therapy aims to heal trauma in young women
- Bringing HIV care to the community: a new test in zambia
- Could intense workouts reverse cognitive decline in older HIV patients?